SRI

Across TCGA pan-cancer cohorts, SRI Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRI data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SRI Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRI expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCEC, COAD, and CHOL are the cancer types where SRI Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.212	0.691	.009	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.561	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRI–UCEC (OS)

Open the UCEC breakdown →